<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04766281</url>
  </required_header>
  <id_info>
    <org_study_id>SJREB-2020-94</org_study_id>
    <nct_id>NCT04766281</nct_id>
  </id_info>
  <brief_title>MLC901 in Moderate Traumatic Brain Injury</brief_title>
  <acronym>ANDROMEDA</acronym>
  <official_title>Safety and Efficacy of MLC901 (NeuroAiD Ii) in Patients With Moderate TBI: A Randomized Double Blind Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of the Philippines</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of the Philippines</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study wants to evaluate whether MLC901 will help improve the condition of adult patients&#xD;
      with moderate traumatic brain injury.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double blind placebo controlled randomized trial to determine whether giving MLC901&#xD;
      for 6 months will improve the outcomes in a adult patients with moderate traumatic brain&#xD;
      injury.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants are assigned to receive either MLC901 or placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GOS-E at 6 months</measure>
    <time_frame>18 months</time_frame>
    <description>This is the most widely used TBI outcome measure with the extended version ranging from 0 (dead) to 8 (full recovery)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality at 6 months</measure>
    <time_frame>18 months</time_frame>
    <description>The number of patients who died in each arm at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral swelling at baseline, 1 &amp; 2 weeks</measure>
    <time_frame>18 months</time_frame>
    <description>Cerebral swelling is assessed by CT-scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow Outcome Scale Extended (GOS-E) at baseline, 1,3 &amp; 9 months</measure>
    <time_frame>18 months</time_frame>
    <description>This clinical scale is the most widely used outcome measure after TBI, with the extended version scoring from 0 (dead) to full recovery (8).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glasgow Coma Scale (GCS) at baseline, 1, 3, 6 &amp; 9 months</measure>
    <time_frame>18 months</time_frame>
    <description>This is a widely used clinical scale to assess the depth and duration of impaired consciousness and coma by measuring motor responsiveness, verbal performance and eye opening. The score ranges from 3 to 15.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment Filipino Version (MoCA-P) at 1,3,6 &amp; 9 months</measure>
    <time_frame>18 months</time_frame>
    <description>This is an adaptation of the MoCA to the Philippine setting, used in the detection of mild cognitive impairment. The scores range between 0-10, with a score of 26 or over considered to be normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frontal Assessment Battery at 1,3,6 &amp; 9 monts</measure>
    <time_frame>18 months</time_frame>
    <description>This battery of tests is used to assess frontal lobe dysfunction, consisting of the following sub tests: conceptualisation, mental flexibility, motor programming, sensitivity to interference, inhibitory control and environmental autonomy.Total scor is from a maximum of 18, with higher scores indicating better performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RiverMead Postconcussion Symptome Questionnaire Score at 1,3,6 &amp; 9 months</measure>
    <time_frame>18 months</time_frame>
    <description>This is a 10 item questionnaire mainly used for patients with mild to moderate TBI. This is a 16 item questionnaire, scored on a 5 point Liberty scale ranging from 0 (not experienced at all) to 4 ( a severe problem).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index (BI) at 1,3,6 &amp; 9 months</measure>
    <time_frame>18 months</time_frame>
    <description>This scale is used to assess functional disability by quantifying patient performance in 10 activities of daily living. The score ranges from 0 (totally dependent) to 100 (fully independent).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale at 1,3,6 &amp; 9 months</measure>
    <time_frame>18 months</time_frame>
    <description>This scale is used to measure levels of anxiety and depression, ranging from 0 to 21,with normal score of 0-7, mild 8-10, moderate 11-14 and severe 15-21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D at 1,3,6 &amp; 9 months (EuroQol Group)</measure>
    <time_frame>18 months</time_frame>
    <description>This instrument describes the health status of respondents in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The score ranges from 0-100, with higher scores for higher health related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety until 9 months: adverse events</measure>
    <time_frame>18 months</time_frame>
    <description>Safety is assessed by checking for the occurence of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance until 6 months</measure>
    <time_frame>18 months</time_frame>
    <description>Compliance is documented by the number of medications taken at set intervals during follow up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Moderate Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>MLC901 (NeuroAiD II)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This consists of extracts from 9 herbal components in a dark blue/light blue capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This consists of a dark brown powder in size 0 dark blue/light blue vegetable capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MLC901</intervention_name>
    <description>This consists of extracts from 9 herbal components in a dark blue/light blue capsule</description>
    <arm_group_label>MLC901 (NeuroAiD II)</arm_group_label>
    <other_name>NeuroAiD II</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This consists of a dark brown powder in size 0 dark blue/light blue vegetable capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-65 years&#xD;
&#xD;
          -  Moderate TBI&#xD;
&#xD;
          -  Presenting at the study site within 7 days of injury&#xD;
&#xD;
          -  Participant or his/her legal representative able to comply with the study protocol and&#xD;
             willing to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Penetrating HI&#xD;
&#xD;
          -  Co-existing severe or unstable injury&#xD;
&#xD;
          -  Physician's medical judgment that surgical intervention is likely within the next 48&#xD;
             hours&#xD;
&#xD;
          -  Physician's medical judgment that participation is not in the participant's best&#xD;
             interest&#xD;
&#xD;
          -  Pre-injury mRS&gt;2&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Inability to take study drug orally or via NGT&#xD;
&#xD;
          -  Participation in another investigational drug study&#xD;
&#xD;
          -  Intake of nootropic drugs which are not standard TBI medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annabell E Chua, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of the Philippines Manila - Philippine General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Annabell E Chua, MD</last_name>
    <phone>+632-85242338</phone>
    <email>aechua@up.edu.ph</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mariano Marcos Memorial Hospital and Medical Center</name>
      <address>
        <city>Batac</city>
        <state>Ilocos Norte</state>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tercy Manalo, M.D.</last_name>
      <email>terc81@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northern Mindanao Medical Center</name>
      <address>
        <city>Cagayan De Oro</city>
        <state>Misamis Oriental</state>
        <zip>9000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vilma Yacapin, M.D.</last_name>
      <email>Penfield100370@yahoo.com.ph</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Philippine General Hospital</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annabell E Chua, M.D.</last_name>
      <phone>0285242338</phone>
      <email>aechua@up.edu.ph</email>
    </contact>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>February 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of the Philippines</investigator_affiliation>
    <investigator_full_name>Annabell Chua</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

